Compare Citius Pharmaceuticals Inc (CTXR) vs VF Corp (VFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs VF Corp — how do they compare? Citius Pharmaceuticals Inc trades at $0.77 (market cap $20.01M), while VF Corp trades at $14.63 (market cap $5.81B). The key difference: VF Corp is far larger — about 290.4× Citius Pharmaceuticals Inc's market cap, and VF Corp pays a 2.44% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | VFC | |
|---|---|---|
Market Cap | $20.01M | $5.81B |
Sector | Health | Consumer Cyclical |
52-Week High | $1.82 | $21.55 |
52-Week Low | $0.48 | $12.21 |
Enterprise Value | $16.23M | $10.09B |
Dividend Yield | — | 2.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.7554, up 11.58% today, with a bullish technical signal from moving averages. The company reported a net loss of $37.43M for 2025, with a negative net income margin of -823.34%, but shows revenue growth from its LYMPHIR launch. Recent news highlights commercial expansion and positive clinical data presentations at ASCO 2026.
The outlook is speculative; analyst consensus is strongly bullish (83.3% Buy), but high cash burn and consistent earnings misses pose significant risks. Investment potential hinges on successful commercialization of LYMPHIR to achieve profitability.
VFC stock trades at $14.69, down 1.41% on the day, reflecting ongoing pressure from recent earnings misses and weak Vans brand performance. Technical indicators are bearish, with the price near key support at $14.00. Fundamentally, revenue has declined from $11.8B in 2022 to $9.5B in 2025, with net losses in 2024 and 2025, though 2026 projects a return to profitability. The company is focused on deleveraging, with debt-to-asset ratio improving to 42.42% in 2025.
The outlook remains challenging due to brand-specific headwinds and macro pressures, but cost controls and a raised fiscal 2027 revenue outlook offer some optimism. Risks include persistent Vans weakness and consumer sentiment, while the consensus price target of $17.44 suggests modest upside if turnaround efforts gain traction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About VF Corp
VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →
